Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company whose news flow reflects its role in life science tools, bioactive reagents, diagnostics, and spatial biology. Company announcements frequently highlight financial results, product launches, collaborations, and participation in healthcare and investor conferences, giving investors and researchers insight into how Bio-Techne is executing its strategy.
Recent press releases include quarterly and annual financial updates, where Bio-Techne reports net sales, segment performance for its Protein Sciences and Diagnostics and Spatial Biology segments, and commentary on market conditions. These earnings communications often discuss organic revenue trends, operating margins, and portfolio decisions such as divestitures of non-core businesses.
Product and technology news from Bio-Techne covers launches of analytical instruments, spatial biology assays, and multiomic workflows. Examples include announcements of next-generation protein analysis systems with multiplexing capabilities, spatial biology platforms that combine RNA and protein detection, and assays that visualize protein-protein interactions within tissue at subcellular resolution. Such updates show how the company is expanding its proteomic analytical tools and spatial biology offerings, which it identifies as growth pillars.
Bio-Techne also issues news about strategic collaborations and licensing agreements. Recent items describe partnerships in AI-enabled protein design, multiomic spatial analysis with academic and industry partners, and initiatives supporting cell and gene therapy manufacturing workflows. In addition, the company regularly announces its participation in major healthcare and investor conferences, where management presents its outlook and strategy.
This TECH news page aggregates these types of updates so readers can follow Bio-Techne’s financial reporting, product innovation, strategic partnerships, and conference activity in one place. Investors, analysts, and scientists can use this feed to monitor developments across the company’s life science tools, diagnostics, and spatial biology businesses.
Bio-Techne (NASDAQ: TECH) announced a strategic collaboration with the Wyss Center Geneva on Dec 11, 2025 to develop an automated workflow for simultaneous RNA and protein detection in 3D tissue specimens. The project aims to extend Bio-Techne's multiomic spatial biology capabilities from 2D into intact 3D samples, enabling high-resolution multiomic analysis in thicker sections.
The collaboration targets automation to reduce manual complexity, accelerate drug discovery and diagnostic development, and support New Approach Methodologies (NAMs) such as organoids and AI-driven predictive modeling to potentially reduce animal testing. Executives from both organizations cited the partnership as a step to broaden accessibility of spatial biology tools for preclinical research.
Bio-Techne (NASDAQ: TECH) launched and shipped its enhanced Leo System on Dec 9, 2025, an upgraded Simple Western platform combining chemiluminescence with dual-channel near-infrared and infrared fluorescence for expanded multiplexing.
Key capabilities include up to 24 targets per sample, support for multiplexing same-weight targets and proteoform pairs (e.g., phosphorylated vs total), resampling and RePlex workflows, processing up to 100 capillaries in three hours, and reported precision of 5–6% variability. The system also includes features to support 21 CFR Part 11 compliance.
Bio-Techne (NASDAQ: TECH) will present at three investor conferences in early December 2025.
Events and times:
- Evercore Healthcare Conference — December 2, 2025 at 8:20 AM ET
- Citi Global Healthcare Conference — December 3, 2025 at 3:15 PM ET
- Nasdaq Investor Conference — December 9, 2025 at 9:30 AM GMT
A live webcast of each presentation will be available via Bio-Techne's investor relations IR Calendar page: https://investors.bio-techne.com/ir-calendar.
Bio-Techne (NASDAQ: TECH) announced on November 18, 2025 a licensing agreement with Monod Bio granting Bio-Techne exclusive commercial rights to a subset of Monod's NovoBody™ Duo molecules, a class of AI-designed bispecific binding proteins.
The deal expands Bio-Techne's recombinant protein and diagnostics portfolio with compact, tunable, multi-specific designs aimed at research and next-generation diagnostics, and is presented as aligning with the company's strategic growth pillars in AI-enabled precision medicine.
Bio-Techne (NASDAQ: TECH) will present at four investor conferences in November 2025. Scheduled presentations:
- UBS Global Healthcare — November 10, 2025 at 10:15 AM ET
- Stifel Healthcare — November 11, 2025 at 9:20 AM ET
- Stephens Investment — November 18, 2025 at 8:00 AM CT
- Jefferies Global Healthcare — November 20, 2025 at 12:30 PM GMT
A live webcast will be available via the company's Investor Relations Calendar at https://investors.bio-techne.com/ir-calendar.
Bio-Techne (NASDAQ: TECH) reported first quarter fiscal 2026 results for the period ended September 30, 2025.
Key figures: net sales $286.6M (down 1% YoY), GAAP EPS $0.24 versus $0.21, adjusted EPS $0.42 (flat YoY), and adjusted operating margin 29.9%. GAAP operating income rose 19% to $47.7M and GAAP operating margin improved to 16.6% from 13.8%.
The company completed the divestiture of Exosome Diagnostics (EPI), cited productivity and cost containment gains, and flagged short- and intermediate-term order timing headwinds in its GMP proteins business tied to customer regulatory progress.
Bio-Techne (NASDAQ: TECH) and Nucleai presented SECOMBIT clinical-trial spatial biology data at SITC 2025 showing AI-integrated, high-plex imaging can identify predictive biomarkers in metastatic melanoma.
Researchers profiled 42 pre-treatment biopsies using the COMET platform and a 28-plex mIF panel; analyses linked specific immune cell locations and interactions to progression-free survival, overall survival, and clinical benefit across three treatment arms. The abstract was selected among the top 150 of ~1,200 submissions. Poster #528 and Bio-Techne booth #603 at SITC 2025 will display the data and new spatial biology products including ProximityScope and extended SPYRE portfolio.
ScaleReady (TECH) announced a $300,000 G-Rex Grant awarded to Sonoma Biotherapeutics to accelerate development of a G-Rex based manufacturing process for gene-modified regulatory T cell (Treg) therapies for clinical investigation, targeting autoimmune disorders. The grant supports transition from open-flask methods to closed, scalable G-Rex devices and integration of ProPak GMP cytokines, process analytical technology, and novel closed-system tools from Wilson Wolf.
ScaleReady reports its G-Rex Grant Program has exceeded $40M in no-cost product commitments; individual awards are up to $300,000.
Bio-Techne (NASDAQ: TECH) launched the ProximityScope™ assay on the Leica Biosystems BOND RX staining platform on October 28, 2025, enabling visualization of functional protein-protein interactions in fixed tissue at subcellular resolution.
The assay produces a visual signal only when two proteins are physically close, integrates with ACD's RNAscope Multiomic LS kit for RNA and protein detection on the same section, and automates spatial multiomic workflows via Leica's BOND RX. The workflow will be showcased at SITC, Nov 7-8, 2025 (Booth 603). Bio-Techne reported over $1.2B net sales in fiscal 2025 and about 3,100 employees.
ScaleReady (TECH) and partners awarded four G‑Rex Grants to Children's National Hospital totaling $375,000 to support translation of cell and gene therapies into the clinic.
Grants: $100,000 to Dr. Patrick Hanley for a G‑Rex CAR‑T manufacturing process; $150,000 shared by Drs. Keller and Hanley to move VST and TAAT workflows into G‑Rex M series bioreactors; $75,000 to Dr. Amy Hont for ATTACK TAAT; $50,000 to Dr. Cruz for CAR‑modified TAAT process development.
ScaleReady reports its G‑Rex Grant Program surpassed $40M of no‑cost product commitments and launched a free LEAN Cell & Gene event series.